Pluronic P85 block copolymer enhances opioid peptide analgesia

Ken A. Witt, Jason D. Huber, Richard D. Egleton, Thomas P Davis

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

Peptide-based drug development is a rapidly growing field within pharmaceutical research. Nevertheless, peptides have found limited clinical use due to several physiological and pathological factors. Pluronic block copolymers represent a growing technology with the potential to enhance efficacy of peptide therapeutics. This investigation assesses Pluronic P85 (P85) and its potential to enhance opioid peptide analgesia. Two opioid peptides, [D-Pen2,D-Pen5]-enkephalin (DPDPE) and biphalin, were examined as to the benefits of P85 coadministration, above (1.0%) and below (0.01%) the critical micelle concentration, with morphine as a nonpeptide control. P85 was examined in vitro to assess blood-brain barrier uptake in association with P-glycoprotein effect, DPDPE and morphine being P-glycoprotein substrates. P85 coadministration with DPDPE and biphalin showed increased (p < 0.01) analgesia with both 0.01 and 1.0% P85. Morphine showed increased (p < 0.01) analgesia with 0.01% P85 only. This increase in analgesia is due to both an increase in peak effect, as well as a prolongation of effect. P85 increased cellular uptake of 125I-DPDPE and [3H]morphine at 0.01% (p < 0.01) and 1.0% (p < 0.01 and p < 0.05, respectively). Cyclosporin-A coadministration with 125I-DPDPE and [3H]morphine increased cellular uptake (p <0.01 and p < 0.05, respectively). 125I-DPDPE and [3H]morphine coadministered with 0.01% P85 and cyclosporin-A increased cellular uptake compared with control (p < 0.01) and compared with cyclosporin-A coadministration without P85 (p < 0.01 and p < 0.05, respectively). This indicates that, in addition to P-gp inhibition, 0.01% P85 increased 125I-DPDPE and [3H]morphine uptake. In our examination, we determined that P85 enhanced the analgesic profile of biphalin, DPDPE, and morphine, both above and below the critical micelle concentration.

Original languageEnglish (US)
Pages (from-to)760-767
Number of pages8
JournalJournal of Pharmacology and Experimental Therapeutics
Volume303
Issue number2
DOIs
StatePublished - Nov 1 2002

Fingerprint

D-Penicillamine (2,5)-Enkephalin
Opioid Peptides
Analgesia
Morphine
Cyclosporine
Poloxamer
Micelles
P-Glycoprotein
Peptides
pluronic block copolymer p85
Blood-Brain Barrier
Analgesics
Technology

ASJC Scopus subject areas

  • Pharmacology

Cite this

Pluronic P85 block copolymer enhances opioid peptide analgesia. / Witt, Ken A.; Huber, Jason D.; Egleton, Richard D.; Davis, Thomas P.

In: Journal of Pharmacology and Experimental Therapeutics, Vol. 303, No. 2, 01.11.2002, p. 760-767.

Research output: Contribution to journalArticle

Witt, Ken A. ; Huber, Jason D. ; Egleton, Richard D. ; Davis, Thomas P. / Pluronic P85 block copolymer enhances opioid peptide analgesia. In: Journal of Pharmacology and Experimental Therapeutics. 2002 ; Vol. 303, No. 2. pp. 760-767.
@article{b9b43a29296849b788b800d8bf222da6,
title = "Pluronic P85 block copolymer enhances opioid peptide analgesia",
abstract = "Peptide-based drug development is a rapidly growing field within pharmaceutical research. Nevertheless, peptides have found limited clinical use due to several physiological and pathological factors. Pluronic block copolymers represent a growing technology with the potential to enhance efficacy of peptide therapeutics. This investigation assesses Pluronic P85 (P85) and its potential to enhance opioid peptide analgesia. Two opioid peptides, [D-Pen2,D-Pen5]-enkephalin (DPDPE) and biphalin, were examined as to the benefits of P85 coadministration, above (1.0{\%}) and below (0.01{\%}) the critical micelle concentration, with morphine as a nonpeptide control. P85 was examined in vitro to assess blood-brain barrier uptake in association with P-glycoprotein effect, DPDPE and morphine being P-glycoprotein substrates. P85 coadministration with DPDPE and biphalin showed increased (p < 0.01) analgesia with both 0.01 and 1.0{\%} P85. Morphine showed increased (p < 0.01) analgesia with 0.01{\%} P85 only. This increase in analgesia is due to both an increase in peak effect, as well as a prolongation of effect. P85 increased cellular uptake of 125I-DPDPE and [3H]morphine at 0.01{\%} (p < 0.01) and 1.0{\%} (p < 0.01 and p < 0.05, respectively). Cyclosporin-A coadministration with 125I-DPDPE and [3H]morphine increased cellular uptake (p <0.01 and p < 0.05, respectively). 125I-DPDPE and [3H]morphine coadministered with 0.01{\%} P85 and cyclosporin-A increased cellular uptake compared with control (p < 0.01) and compared with cyclosporin-A coadministration without P85 (p < 0.01 and p < 0.05, respectively). This indicates that, in addition to P-gp inhibition, 0.01{\%} P85 increased 125I-DPDPE and [3H]morphine uptake. In our examination, we determined that P85 enhanced the analgesic profile of biphalin, DPDPE, and morphine, both above and below the critical micelle concentration.",
author = "Witt, {Ken A.} and Huber, {Jason D.} and Egleton, {Richard D.} and Davis, {Thomas P}",
year = "2002",
month = "11",
day = "1",
doi = "10.1124/jpet.102.039545",
language = "English (US)",
volume = "303",
pages = "760--767",
journal = "Journal of Pharmacology and Experimental Therapeutics",
issn = "0022-3565",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "2",

}

TY - JOUR

T1 - Pluronic P85 block copolymer enhances opioid peptide analgesia

AU - Witt, Ken A.

AU - Huber, Jason D.

AU - Egleton, Richard D.

AU - Davis, Thomas P

PY - 2002/11/1

Y1 - 2002/11/1

N2 - Peptide-based drug development is a rapidly growing field within pharmaceutical research. Nevertheless, peptides have found limited clinical use due to several physiological and pathological factors. Pluronic block copolymers represent a growing technology with the potential to enhance efficacy of peptide therapeutics. This investigation assesses Pluronic P85 (P85) and its potential to enhance opioid peptide analgesia. Two opioid peptides, [D-Pen2,D-Pen5]-enkephalin (DPDPE) and biphalin, were examined as to the benefits of P85 coadministration, above (1.0%) and below (0.01%) the critical micelle concentration, with morphine as a nonpeptide control. P85 was examined in vitro to assess blood-brain barrier uptake in association with P-glycoprotein effect, DPDPE and morphine being P-glycoprotein substrates. P85 coadministration with DPDPE and biphalin showed increased (p < 0.01) analgesia with both 0.01 and 1.0% P85. Morphine showed increased (p < 0.01) analgesia with 0.01% P85 only. This increase in analgesia is due to both an increase in peak effect, as well as a prolongation of effect. P85 increased cellular uptake of 125I-DPDPE and [3H]morphine at 0.01% (p < 0.01) and 1.0% (p < 0.01 and p < 0.05, respectively). Cyclosporin-A coadministration with 125I-DPDPE and [3H]morphine increased cellular uptake (p <0.01 and p < 0.05, respectively). 125I-DPDPE and [3H]morphine coadministered with 0.01% P85 and cyclosporin-A increased cellular uptake compared with control (p < 0.01) and compared with cyclosporin-A coadministration without P85 (p < 0.01 and p < 0.05, respectively). This indicates that, in addition to P-gp inhibition, 0.01% P85 increased 125I-DPDPE and [3H]morphine uptake. In our examination, we determined that P85 enhanced the analgesic profile of biphalin, DPDPE, and morphine, both above and below the critical micelle concentration.

AB - Peptide-based drug development is a rapidly growing field within pharmaceutical research. Nevertheless, peptides have found limited clinical use due to several physiological and pathological factors. Pluronic block copolymers represent a growing technology with the potential to enhance efficacy of peptide therapeutics. This investigation assesses Pluronic P85 (P85) and its potential to enhance opioid peptide analgesia. Two opioid peptides, [D-Pen2,D-Pen5]-enkephalin (DPDPE) and biphalin, were examined as to the benefits of P85 coadministration, above (1.0%) and below (0.01%) the critical micelle concentration, with morphine as a nonpeptide control. P85 was examined in vitro to assess blood-brain barrier uptake in association with P-glycoprotein effect, DPDPE and morphine being P-glycoprotein substrates. P85 coadministration with DPDPE and biphalin showed increased (p < 0.01) analgesia with both 0.01 and 1.0% P85. Morphine showed increased (p < 0.01) analgesia with 0.01% P85 only. This increase in analgesia is due to both an increase in peak effect, as well as a prolongation of effect. P85 increased cellular uptake of 125I-DPDPE and [3H]morphine at 0.01% (p < 0.01) and 1.0% (p < 0.01 and p < 0.05, respectively). Cyclosporin-A coadministration with 125I-DPDPE and [3H]morphine increased cellular uptake (p <0.01 and p < 0.05, respectively). 125I-DPDPE and [3H]morphine coadministered with 0.01% P85 and cyclosporin-A increased cellular uptake compared with control (p < 0.01) and compared with cyclosporin-A coadministration without P85 (p < 0.01 and p < 0.05, respectively). This indicates that, in addition to P-gp inhibition, 0.01% P85 increased 125I-DPDPE and [3H]morphine uptake. In our examination, we determined that P85 enhanced the analgesic profile of biphalin, DPDPE, and morphine, both above and below the critical micelle concentration.

UR - http://www.scopus.com/inward/record.url?scp=0036828225&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036828225&partnerID=8YFLogxK

U2 - 10.1124/jpet.102.039545

DO - 10.1124/jpet.102.039545

M3 - Article

C2 - 12388663

AN - SCOPUS:0036828225

VL - 303

SP - 760

EP - 767

JO - Journal of Pharmacology and Experimental Therapeutics

JF - Journal of Pharmacology and Experimental Therapeutics

SN - 0022-3565

IS - 2

ER -